Intrexon Corp (XON) 28.08 $XON Intrexon to Deve
Post# of 273327
Posted On: 09/23/2016 9:16:07 AM
Intrexon Corp (XON) 28.08 $XON
Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
PR Newswire - 1 hr 15 mins ago
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it has entered into Exclusive Channel Collaborations (ECC) with two startups backed by the Harvest Intrexon Enterprise Fund, sponsored by Harvest Capital Strategies, LLC. Through Intrexon's proprietary ActoBiotics(TM) Lactococcus lactis platform, these companies will pursue new approaches to deliver disease-modifying therapies:
JMP: 5.54 (+0.03), XON: 28.08 (+0.04)
Valeant Pharmaceuticals trade offers a 9% return in 122 days, or find similar option trades on Cabelas Incorporated, Gigamon Incorporated, Skechers, and Intrexon
PR Newswire - Tue Sep 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CAB, GIMO, SKX, VRX, and XON.
GIMO: 54.29 (+0.28), VRX: 26.72 (-0.13), SKX: 21.93 (+0.71), XON: 28.08 (+0.04), CAB: 51.19 (+1.11)
Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire - Mon Sep 19, 7:00AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that two additional adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), satisfying enrollment in one of two cohorts in the Phase I portion of the trial.
FCSC: 0.78 (unch), XON: 28.08 (+0.04)
Exemplar Genetics ExeGen® Cystic Fibrosis Research Model Utilized in Development of New Gene Therapy Treatments
PR Newswire - Tue Sep 13, 7:00AM CDT
Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publications in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen® CFTR miniswine research models to help define and develop effective gene therapies for cystic fibrosis.
XON: 28.08 (+0.04)
Florida Speaker-Designate and House Members Request Emergency Authorization to Combat Aedes aegypti Mosquitoes with Oxitec Technology
PR Newswire - Wed Sep 07, 12:21PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today reports a bipartisan coalition of 61 Florida House members led by Speaker-designate Richard Corcoran and Democratic Leader-designate Janet Cruz have issued a letter urging the U.S. Federal Government to take proactive steps including Emergency Use Authorization (EUA) to allow Florida's state and local governments to use Oxitec's genetically engineered Friendly(TM) Aedes to suppress Aedes aegypti mosquitoes that transmit Zika, chikungunya, dengue and other dangerous viruses to humans.
XON: 28.08 (+0.04)
Oxitec and Piracicaba City Hall Start Release of Friendly(TM) Aedes
PR Newswire Europe - Tue Sep 06, 8:01AM CDT
OXFORD, England, September 6, 2016 /PRNewswire/ --
XON: 28.08 (+0.04)
Purcell Julie & Lefkowitz LLP Is Investigating Intrexon Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Thu Sep 01, 6:21AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intrexon Corporation (NYSE: XON).
XON: 28.08 (+0.04)
These Two Companies Are Working On The Zika Virus Cure
Ryan McQueeney - Zacks Investment Research - Wed Aug 31, 11:57AM CDT
As the Zika virus continues to spread, these two companies are looking to find the cure first.
INO: 9.74 (-0.06), XON: 28.08 (+0.04)
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 5.83 (unch), XON: 28.08 (+0.04), WFC: 45.52 (-0.20)
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
BusinessWire - Tue Aug 30, 7:15AM CDT
Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) in response to the Company's request for a Type C meeting, concerning Phase 2 study protocols for the Company's OM therapeutic candidate, AG013. As part of the clinical protocol for the study, Oragenics expects to file the Investigational New Drug (IND) update in late 2016 and initiate the study with AG013 in the United States and Europe during early 2017.
XON: 28.08 (+0.04), OGEN: 0.55 (-0.02)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.74 (-0.06), ANIP: 66.81 (+1.69), GERN: 2.22 (-0.03), XON: 28.08 (+0.04)
Learn how to target a 20% return on Apple, or get option-trade ideas on Resolute Energy Corporation, Autodesk, Intrexon and Energy Transfer Equity or any stock you choose
PR Newswire - Mon Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ADSK, ETE, REN, and XON.
REN: 22.50 (-0.14), XON: 28.08 (+0.04), ETE: 16.94 (+0.03), AAPL: 114.47 (-0.15), ADSK: 72.35 (+0.66)
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
BusinessWire - Tue Aug 23, 7:15AM CDT
Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug (IND) enabling studies.
XON: 28.08 (+0.04), OGEN: 0.55 (-0.02)
Covered Call reports for Gilead Sciences, Intrexon, Ralph Lauren, Smith & Wesson and Eros International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EROS, GILD, RL, SWHC, and XON.
GILD: 81.74 (+0.22), XON: 28.08 (+0.04), RL: 98.97 (-0.14), EROS: 16.24 (-0.01), SWHC: 27.70 (+0.09)
Arctic® Fuji apple one step closer to U.S. regulatory approval
PR Newswire - Thu Aug 11, 7:30AM CDT
The U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) has publicly shared the final version of Okanagan Specialty Fruits Inc.'s (OSF) petition seeking regulatory approval for Arctic® Fuji apples, a nonbrowning variety produced through biotechnology.
XON: 28.08 (+0.04)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.83 (unch), ANIP: 66.81 (+1.69), XON: 28.08 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 5.83 (unch), FCSC: 0.78 (unch), XON: 28.08 (+0.04)
Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
PR Newswire - 1 hr 15 mins ago
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it has entered into Exclusive Channel Collaborations (ECC) with two startups backed by the Harvest Intrexon Enterprise Fund, sponsored by Harvest Capital Strategies, LLC. Through Intrexon's proprietary ActoBiotics(TM) Lactococcus lactis platform, these companies will pursue new approaches to deliver disease-modifying therapies:
JMP: 5.54 (+0.03), XON: 28.08 (+0.04)
Valeant Pharmaceuticals trade offers a 9% return in 122 days, or find similar option trades on Cabelas Incorporated, Gigamon Incorporated, Skechers, and Intrexon
PR Newswire - Tue Sep 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CAB, GIMO, SKX, VRX, and XON.
GIMO: 54.29 (+0.28), VRX: 26.72 (-0.13), SKX: 21.93 (+0.71), XON: 28.08 (+0.04), CAB: 51.19 (+1.11)
Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire - Mon Sep 19, 7:00AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that two additional adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), satisfying enrollment in one of two cohorts in the Phase I portion of the trial.
FCSC: 0.78 (unch), XON: 28.08 (+0.04)
Exemplar Genetics ExeGen® Cystic Fibrosis Research Model Utilized in Development of New Gene Therapy Treatments
PR Newswire - Tue Sep 13, 7:00AM CDT
Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publications in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen® CFTR miniswine research models to help define and develop effective gene therapies for cystic fibrosis.
XON: 28.08 (+0.04)
Florida Speaker-Designate and House Members Request Emergency Authorization to Combat Aedes aegypti Mosquitoes with Oxitec Technology
PR Newswire - Wed Sep 07, 12:21PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today reports a bipartisan coalition of 61 Florida House members led by Speaker-designate Richard Corcoran and Democratic Leader-designate Janet Cruz have issued a letter urging the U.S. Federal Government to take proactive steps including Emergency Use Authorization (EUA) to allow Florida's state and local governments to use Oxitec's genetically engineered Friendly(TM) Aedes to suppress Aedes aegypti mosquitoes that transmit Zika, chikungunya, dengue and other dangerous viruses to humans.
XON: 28.08 (+0.04)
Oxitec and Piracicaba City Hall Start Release of Friendly(TM) Aedes
PR Newswire Europe - Tue Sep 06, 8:01AM CDT
OXFORD, England, September 6, 2016 /PRNewswire/ --
XON: 28.08 (+0.04)
Purcell Julie & Lefkowitz LLP Is Investigating Intrexon Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Thu Sep 01, 6:21AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intrexon Corporation (NYSE: XON).
XON: 28.08 (+0.04)
These Two Companies Are Working On The Zika Virus Cure
Ryan McQueeney - Zacks Investment Research - Wed Aug 31, 11:57AM CDT
As the Zika virus continues to spread, these two companies are looking to find the cure first.
INO: 9.74 (-0.06), XON: 28.08 (+0.04)
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 5.83 (unch), XON: 28.08 (+0.04), WFC: 45.52 (-0.20)
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
BusinessWire - Tue Aug 30, 7:15AM CDT
Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) in response to the Company's request for a Type C meeting, concerning Phase 2 study protocols for the Company's OM therapeutic candidate, AG013. As part of the clinical protocol for the study, Oragenics expects to file the Investigational New Drug (IND) update in late 2016 and initiate the study with AG013 in the United States and Europe during early 2017.
XON: 28.08 (+0.04), OGEN: 0.55 (-0.02)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.74 (-0.06), ANIP: 66.81 (+1.69), GERN: 2.22 (-0.03), XON: 28.08 (+0.04)
Learn how to target a 20% return on Apple, or get option-trade ideas on Resolute Energy Corporation, Autodesk, Intrexon and Energy Transfer Equity or any stock you choose
PR Newswire - Mon Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ADSK, ETE, REN, and XON.
REN: 22.50 (-0.14), XON: 28.08 (+0.04), ETE: 16.94 (+0.03), AAPL: 114.47 (-0.15), ADSK: 72.35 (+0.66)
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
BusinessWire - Tue Aug 23, 7:15AM CDT
Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug (IND) enabling studies.
XON: 28.08 (+0.04), OGEN: 0.55 (-0.02)
Covered Call reports for Gilead Sciences, Intrexon, Ralph Lauren, Smith & Wesson and Eros International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EROS, GILD, RL, SWHC, and XON.
GILD: 81.74 (+0.22), XON: 28.08 (+0.04), RL: 98.97 (-0.14), EROS: 16.24 (-0.01), SWHC: 27.70 (+0.09)
Arctic® Fuji apple one step closer to U.S. regulatory approval
PR Newswire - Thu Aug 11, 7:30AM CDT
The U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) has publicly shared the final version of Okanagan Specialty Fruits Inc.'s (OSF) petition seeking regulatory approval for Arctic® Fuji apples, a nonbrowning variety produced through biotechnology.
XON: 28.08 (+0.04)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.83 (unch), ANIP: 66.81 (+1.69), XON: 28.08 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 5.83 (unch), FCSC: 0.78 (unch), XON: 28.08 (+0.04)
(0)
(0)